SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Vida Ventures Advisors, LLC

CIK 0001831423 · 40 BROAD STREET, SUITE 201, BOSTON, MA, 02109 · 6176489100

Reported Value
$84M
Q4 2023
Positions
7
Filings on Record
21
2019–present window
Filed
Jan 5, 2024
original filing

Summary

Vida Ventures Advisors, LLC reported $84M in U.S.-listed holdings across 7 positions for Q4 2023.

The portfolio is heavily concentrated: 260 alone accounts for 37.3% of reported value.

Compared with Q3 2023, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+4.3%
vs prior filed quarter
Largest Position
+37.3%
Centessa Pharmaceuticals

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q3 ’20: $160MQ3 ’20Q4 ’20: $487MQ1 ’21: $396MQ2 ’21: $399MQ2 ’21Q3 ’21: $349MQ4 ’21: $267MQ1 ’22: $172MQ1 ’22Q2 ’22: $118MQ3 ’22: $111MQ4 ’22: $74MQ4 ’22Q1 ’23: $73MQ2 ’23: $77MQ3 ’23: $65MQ3 ’23Q4 ’23: $84MQ1 ’24: $180MQ2 ’24: $91MQ2 ’24Q3 ’24: $139MQ4 ’24: $146MQ1 ’25: $14MQ1 ’25Q2 ’25: $16MQ3 ’25: $29Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 50.1%ADR: 49.4%Other: 0.5%
  • Common Stock · 50.1% · $42M
  • ADR · 49.4% · $41M
  • Other · 0.5% · $443,628

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Praxis Precision Medicines, Inc.SOLD OUT−1.47M0−$3M$0
DYNDyne Therapeutics, Inc.TRIMMED−145.2K2.07M+$8M$28M
LIANYLianBioHELD+02.28M+$7M$10M
260Centessa Pharmaceuticals plcHELD+03.93M+$6M$31M
KNTEUSDKinnate Biopharma, Inc.HELD+02.21M+$2M$5M
Ikena Oncology, Inc.HELD+0225.2K−$531,453$443,628
KRON1USDKronos Bio, Inc.HELD+02.77M−$138,265$3M
ALLOAllogene Therapeutics, Inc.HELD+01.80M+$71,926$6M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

7 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1260Centessa Pharmaceuticals plchistory →Ordinary Shares37.26%$31M3.93M
2DYNDyne Therapeutics, Inc.history →Common Stock32.85%$28M2.07M
3LIANYLianBiohistory →Ordinary Shares12.14%$10M2.28M
4ALLOAllogene Therapeutics, Inc.history →Common Stock6.87%$6M1.80M
5KNTEUSDKinnate Biopharma, Inc.history →Common Stock6.23%$5M2.21M
6KRON1USDKronos Bio, Inc.history →Common Stock4.12%$3M2.77M
7Ikena Oncology, Inc.Common Stock0.53%$443,628225.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2025$29M2Nov 3, 202513F-HRchanges · EDGAR ↗
Q2 2025$16M2Jul 10, 202513F-HRchanges · EDGAR ↗
Q1 2025$14M3Apr 3, 202513F-HRchanges · EDGAR ↗
Q4 2024$146M6Jan 21, 202513F-HRchanges · EDGAR ↗
Q3 2024$139M6Oct 8, 202413F-HRchanges · EDGAR ↗
Q2 2024$91M5Jul 10, 202413F-HRchanges · EDGAR ↗
Q1 2024$180M5Apr 12, 202413F-HRchanges · EDGAR ↗
Q4 2023$84M7Jan 5, 202413F-HRchanges · EDGAR ↗
Q3 2023$65M8Oct 3, 202313F-HRchanges · EDGAR ↗
Q2 2023$77M7Jul 19, 202313F-HRchanges · EDGAR ↗
Q1 2023$73M7Apr 13, 202313F-HRchanges · EDGAR ↗
Q4 2022$74M7Feb 8, 202313F-HRchanges · EDGAR ↗
Q3 2022$111M8Oct 5, 202213F-HRchanges · EDGAR ↗
Q2 2022$118M8Jul 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$172M8May 4, 202213F-HRchanges · EDGAR ↗
Q4 2021$267M8Feb 10, 202213F-HRchanges · EDGAR ↗
Q3 2021$349M8Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$399M9Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$396M8May 11, 202113F-HRchanges · EDGAR ↗
Q4 2020$487M8Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$160M5Nov 12, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.